U
PhaseBio Pharmaceuticals, Inc. PHASQ
OTC PK
Recommendation
--
Prev Close
$0.000001
Volume
--
Avg Vol (90D)
1,228
Market Cap
--
Dividend & Yield
--
52-Week Range
$0.00 - $0.001
P/E (TTM)
0.00
EPS (TTM)
-$2.13
My Lists My Alerts
Rating
Reward
U
Unrated
Risk
U
Unrated
Rating Factors
Growth Index
Unrated
Efficiency Index
Unrated
Solvency Index
Unrated
Total Return Index
Unrated
Volatility Index
Unrated
Dividend Index
Unrated
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
$818.00K
EBITDA (TTM)
-$102.26M
EBIT (TTM)
-$104.20M
Net Income (TTM)
-$102.84M
Balance Sheet
Total Assets (Q)
$22.17M
Total Debt (Q)
$5.37M
Total Liabilities (Q)
$139.56M
Book Value Per Share (Q)
-$2.35
Cash Flow
Cash from Operations (TTM)
-$59.42M
Cash from Investing (TTM)
-$2.40M
Cash from Financing (TTM)
$5.17M
Net Change in Cash (TTM)
-$56.65M
Filings
Filing Date
Friday, August 12, 2022
Period Date
Thursday, June 30, 2022
Next Filing
(est)
Price History
Loading...
Beta
-111.38
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Dec 08, 2023 - $0.00
52-week High
Dec 01, 2023 - $0.001
Valuation
Market Cap
-- - --
Enterprise Value
--
Price/Sales (TTM)
0.00
Price/Book (Q)
0.00
Dividends and Shares
Shares Outstanding
49.18M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
phasebio.com
Phone Number
610 981 6500
Address
1 Great Valley Parkway
Malvern, PA 19355
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
On September 30, 2024, PhaseBio Pharmaceuticals, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. PhaseBio Pharmaceuticals, Inc., a clinical-stage... more
Weiss Ratings